{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:49:47Z","timestamp":1795027787581,"version":"4.10.2"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:00:00Z","timestamp":1700870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:00:00Z","timestamp":1700870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Psoriasis is a chronic inflammatory skin disease that affects millions of people worldwide. Sulforaphane (SFN) has been shown to have anti-inflammatory and antioxidant properties. In this study, we investigated the effects of SFN on a mouse model of psoriasis induced by imiquimod (IMQ) and its underlying molecular mechanism. Mice treated with SFN showed significant improvement in psoriatic symptoms, including reduced erythema, scales, and cutaneous thickness. Histopathological analysis and immunohistochemical staining revealed decreased expression of K16, K17, and Ki67 in SFN-treated mice, indicating reduced abnormal differentiation of keratinocytes and cutaneous inflammation. SFN treatment also reduced the activation of STAT3 and NF-\u03baB pathways and downregulated pro-inflammatory cytokines IL-1\u03b2, IL-6, and CCL2. In vitro experiments using HaCaT cells demonstrated that SFN inhibited IL-22 and TNF-\u03b1-induced activation of inflammatory pathways and keratinocyte proliferation. Network pharmacology analysis suggested that the KEAP1-NRF2 pathway might be involved in the protective effects of SFN on psoriasis. We observed reduced NRF2 expression in human psoriatic lesions, and subsequent experiments showed that SFN activated KEAP1-NRF2 pathway in vivo and in vitro. Importantly, NRF2-deficient mice exhibited aggravated psoriasis-like symptoms and reduced response to SFN treatment. Our findings indicate that SFN ameliorates psoriasis symptoms and inflammation through the KEAP1-NRF2 pathway, suggesting a potential therapeutic role for SFN in the treatment of psoriasis.<\/jats:p>","DOI":"10.1038\/s41419-023-06234-9","type":"journal-article","created":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T03:02:13Z","timestamp":1700881333000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":103,"title":["Sulforaphane alleviates psoriasis by enhancing antioxidant defense through KEAP1-NRF2 Pathway activation and attenuating inflammatory signaling"],"prefix":"10.1038","volume":"14","author":[{"given":"Chujun","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaode","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9299-4716","authenticated-orcid":false,"given":"Junaid","family":"Wazir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renwei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binjia","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyuan","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyongyi","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2868-5112","authenticated-orcid":false,"given":"Hongwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonglan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,25]]},"reference":[{"key":"6234_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. 2021;397:1301\u201315.","journal-title":"Lancet"},{"key":"6234_CR2","doi-asserted-by":"publisher","first-page":"9294","DOI":"10.3390\/ijms22179294","volume":"22","author":"K Dopytalska","year":"2021","unstructured":"Dopytalska K, Ciechanowicz P, Wiszniewski K, Szyma\u0144ska E, Walecka I. The role of epigenetic factors in psoriasis. Int J Mol Sci. 2021;22:9294.","journal-title":"Int J Mol Sci"},{"key":"6234_CR3","doi-asserted-by":"publisher","first-page":"6206","DOI":"10.3390\/ijms21176206","volume":"21","author":"J Ple\u0144kowska","year":"2020","unstructured":"Ple\u0144kowska J, Gabig-Cimi\u0144ska M, Mozolewski P. Oxidative stress as an important contributor to the pathogenesis of psoriasis. Int J Mol Sci. 2020;21:6206.","journal-title":"Int J Mol Sci"},{"key":"6234_CR4","doi-asserted-by":"publisher","first-page":"112142","DOI":"10.1016\/j.biopha.2021.112142","volume":"143","author":"AQ Khan","year":"2021","unstructured":"Khan AQ, Rashid K, AlAmodi AA, Agha MV, Akhtar S, Hakeem I, et al. Reactive oxygen species (ROS) in cancer pathogenesis and therapy: an update on the role of ROS in anticancer action of benzophenanthridine alkaloids. Biomed Pharmacother. 2021;143:112142.","journal-title":"Biomed Pharmacother"},{"key":"6234_CR5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/10715762.2019.1648800","volume":"53","author":"SP Cannav\u00f2","year":"2019","unstructured":"Cannav\u00f2 SP, Riso G, Casciaro M, Di Salvo E, Gangemi S. Oxidative stress involvement in psoriasis: a systematic review. Free Radic Res. 2019;53:829\u201340.","journal-title":"Free Radic Res"},{"key":"6234_CR6","doi-asserted-by":"publisher","first-page":"708","DOI":"10.4103\/ijmr.IJMR_717_16","volume":"146","author":"K Asha","year":"2017","unstructured":"Asha K, Singal A, Sharma SB, Arora VK, Aggarwal A. Dyslipidaemia & oxidative stress in patients of psoriasis: emerging cardiovascular risk factors. Indian J Med Res. 2017;146:708\u201313.","journal-title":"Indian J Med Res"},{"key":"6234_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12929-016-0268-x","volume":"23","author":"I Peluso","year":"2016","unstructured":"Peluso I, Cavaliere A, Palmery M. Plasma total antioxidant capacity and peroxidation biomarkers in psoriasis. J Biomed Sci. 2016;23:52.","journal-title":"J Biomed Sci"},{"key":"6234_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jdermsci.2012.06.006","volume":"68","author":"T Bito","year":"2012","unstructured":"Bito T, Nishigori C. Impact of reactive oxygen species on keratinocyte signaling pathways. J Dermatol Sci. 2012;68:3\u20138.","journal-title":"J Dermatol Sci"},{"key":"6234_CR9","doi-asserted-by":"publisher","first-page":"10799","DOI":"10.3390\/ijms221910799","volume":"22","author":"K Nakai","year":"2021","unstructured":"Nakai K, Tsuruta D. What are reactive oxygen species, free radicals, and oxidative stress in skin diseases? Int J Mol Sci. 2021;22:10799.","journal-title":"Int J Mol Sci"},{"key":"6234_CR10","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1101\/gad.237081.113","volume":"28","author":"V Pekovic-Vaughan","year":"2014","unstructured":"Pekovic-Vaughan V, Gibbs J, Yoshitane H, Yang N, Pathiranage D, Guo B, et al. The circadian clock regulates rhythmic activation of the NRF2\/glutathione-mediated antioxidant defense pathway to modulate pulmonary fibrosis. Genes Dev. 2014;28:548\u201360.","journal-title":"Genes Dev"},{"key":"6234_CR11","doi-asserted-by":"publisher","first-page":"78ra32","DOI":"10.1126\/scitranslmed.3002042","volume":"3","author":"CJ Harvey","year":"2011","unstructured":"Harvey CJ, Thimmulappa RK, Sethi S, Kong X, Yarmus L, Brown RH, et al. Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model. Sci Transl Med. 2011;3:78ra32.","journal-title":"Sci Transl Med"},{"key":"6234_CR12","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1136\/gut.2008.149039","volume":"58","author":"G Kallifatidis","year":"2009","unstructured":"Kallifatidis G, Rausch V, Baumann B, Apel A, Beckermann BM, Groth A, et al. Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut. 2009;58:949\u201363.","journal-title":"Gut"},{"key":"6234_CR13","first-page":"e13886","volume":"46","author":"H Iahtisham Ul","year":"2022","unstructured":"Iahtisham Ul H, Khan S, Awan KA, Iqbal MJ. Sulforaphane as a potential remedy against cancer: comprehensive mechanistic review. J Food Biochem. 2022;46:e13886.","journal-title":"J Food Biochem"},{"key":"6234_CR14","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.clnu.2019.03.022","volume":"39","author":"N Mazarakis","year":"2020","unstructured":"Mazarakis N, Snibson K, Licciardi PV, Karagiannis TC. The potential use of l-sulforaphane for the treatment of chronic inflammatory diseases: a review of the clinical evidence. Clin Nutr. 2020;39:664\u201375.","journal-title":"Clin Nutr"},{"key":"6234_CR15","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/ptr.6572","volume":"34","author":"H Rafiei","year":"2020","unstructured":"Rafiei H, Ashrafizadeh M, Ahmadi Z. MicroRNAs as novel targets of sulforaphane in cancer therapy: the beginning of a new tale? Phytother Res. 2020;34:721\u20138.","journal-title":"Phytother Res"},{"key":"6234_CR16","doi-asserted-by":"publisher","first-page":"D1152","DOI":"10.1093\/nar\/gku893","volume":"43","author":"J Kamens","year":"2015","unstructured":"Kamens J. The Addgene repository: an international nonprofit plasmid and data resource. Nucleic Acids Res. 2015;43:D1152\u20137.","journal-title":"Nucleic Acids Res"},{"key":"6234_CR17","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/j.1365-2133.1995.tb02696.x","volume":"133","author":"IM Leigh","year":"1995","unstructured":"Leigh IM, Navsaria H, Purkis PE, McKay IA, Bowden PE, Riddle PN. Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro. Br J Dermatol. 1995;133:501\u201311.","journal-title":"Br J Dermatol"},{"key":"6234_CR18","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3390\/cells8080807","volume":"8","author":"X Zhang","year":"2019","unstructured":"Zhang X, Yin M, Zhang LJ. Keratin 6, 16 and 17-critical barrier alarmin molecules in skin wounds and psoriasis. Cells. 2019;8:807.","journal-title":"Cells"},{"key":"6234_CR19","first-page":"735","volume":"17","author":"SA Kim","year":"2018","unstructured":"Kim SA, Ryu YW, Kwon JI, Choe MS, Jung JW, Cho JW. Differential expression of cyclin D1, Ki\u201167, pRb, and p53 in psoriatic skin lesions and normal skin. Mol Med Rep. 2018;17:735\u201342.","journal-title":"Mol Med Rep"},{"key":"6234_CR20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jaut.2015.07.008","volume":"64","author":"JL Harden","year":"2015","unstructured":"Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: a comprehensive review. J Autoimmun. 2015;64:66\u201373.","journal-title":"J Autoimmun"},{"key":"6234_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jdermsci.2012.11.002","volume":"69","author":"AM Goldminz","year":"2013","unstructured":"Goldminz AM, Au SC, Kim N, Gottlieb AB, Lizzul PF. NF-\u03baB: an essential transcription factor in psoriasis. J Dermatol Sci. 2013;69:89\u201394.","journal-title":"J Dermatol Sci"},{"key":"6234_CR22","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jid.2018.07.025","volume":"139","author":"Y Cai","year":"2019","unstructured":"Cai Y, Xue F, Quan C, Qu M, Liu N, Zhang Y, et al. A critical role of the IL-1\u03b2-IL-1R signaling pathway in skin inflammation and psoriasis pathogenesis. J Invest Dermatol. 2019;139:146\u201356.","journal-title":"J Invest Dermatol"},{"key":"6234_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1359-6101(02)00027-8","volume":"13","author":"K Ishihara","year":"2002","unstructured":"Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 2002;13:357\u201368.","journal-title":"Cytokine Growth Factor Rev"},{"key":"6234_CR24","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.cyto.2017.12.010","volume":"110","author":"S Behfar","year":"2018","unstructured":"Behfar S, Hassanshahi G, Nazari A, Khorramdelazad H. A brief look at the role of monocyte chemoattractant protein-1 (CCL2) in the pathophysiology of psoriasis. Cytokine. 2018;110:226\u201331.","journal-title":"Cytokine"},{"key":"6234_CR25","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.autrev.2013.11.008","volume":"13","author":"X Yang","year":"2014","unstructured":"Yang X, Zheng SG. Interleukin-22: a likely target for treatment of autoimmune diseases. Autoimmun Rev. 2014;13:615\u201320.","journal-title":"Autoimmun Rev"},{"key":"6234_CR26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/eji.201747017","volume":"48","author":"M Tohyama","year":"2018","unstructured":"Tohyama M, Shirakata Y, Hanakawa Y, Dai X, Shiraishi K, Murakami M, et al. Bcl-3 induced by IL-22 via STAT3 activation acts as a potentiator of psoriasis-related gene expression in epidermal keratinocytes. Eur J Immunol. 2018;48:168\u201379.","journal-title":"Eur J Immunol"},{"key":"6234_CR27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40259-018-0283-4","volume":"32","author":"RJ Moots","year":"2018","unstructured":"Moots RJ, Curiale C, Petersel D, Rolland C, Jones H, Mysler E. Efficacy and safety outcomes for originator TNF inhibitors and biosimilars in rheumatoid arthritis and psoriasis trials: a systematic literature review. BioDrugs. 2018;32:193\u20139.","journal-title":"BioDrugs"},{"key":"6234_CR28","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1089\/ars.2017.7342","volume":"29","author":"C Tonelli","year":"2018","unstructured":"Tonelli C, Chio IIC, Tuveson DA. Transcriptional regulation by Nrf2. Antioxid Redox Signal. 2018;29:1727\u201345.","journal-title":"Antioxid Redox Signal"},{"key":"6234_CR29","doi-asserted-by":"publisher","first-page":"e00099","DOI":"10.1128\/MCB.00099-20","volume":"40","author":"L Baird","year":"2020","unstructured":"Baird L, Yamamoto M. The molecular mechanisms regulating the KEAP1-NRF2 pathway. Mol Cell Biol. 2020;40:e00099\u201320.","journal-title":"Mol Cell Biol"},{"key":"6234_CR30","doi-asserted-by":"publisher","first-page":"101950","DOI":"10.1016\/j.redox.2021.101950","volume":"41","author":"D Ross","year":"2021","unstructured":"Ross D, Siegel D. The diverse functionality of NQO1 and its roles in redox control. Redox Biol. 2021;41:101950.","journal-title":"Redox Biol"},{"key":"6234_CR31","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1007\/s13346-021-01031-3","volume":"12","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Liu T, Zhu S, Pi J, Guo P, Qi D, et al. Natural medicine combined with nanobased topical delivery systems: a new strategy to treat psoriasis. Drug Deliv Transl Res. 2022;12:1326\u201338.","journal-title":"Drug Deliv Transl Res"},{"key":"6234_CR32","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.3390\/ijms20102558","volume":"20","author":"TH Huang","year":"2019","unstructured":"Huang TH, Lin CF, Alalaiwe A, Yang SC, Fang JY. Apoptotic or antiproliferative activity of natural products against keratinocytes for the treatment of psoriasis. Int J Mol Sci. 2019;20:2558.","journal-title":"Int J Mol Sci"},{"key":"6234_CR33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s12272-020-01225-2","volume":"43","author":"MM Kamal","year":"2020","unstructured":"Kamal MM, Akter S, Lin CN, Nazzal S. Sulforaphane as an anticancer molecule: mechanisms of action, synergistic effects, enhancement of drug safety, and delivery systems. Arch Pharm Res. 2020;43:371\u201384.","journal-title":"Arch Pharm Res"},{"key":"6234_CR34","doi-asserted-by":"publisher","first-page":"5440","DOI":"10.1002\/ptr.7176","volume":"35","author":"B Mangla","year":"2021","unstructured":"Mangla B, Javed S, Sultan MH, Kumar P, Kohli K, Najmi A, et al. Sulforaphane: a review of its therapeutic potentials, advances in its nanodelivery, recent patents, and clinical trials. Phytother Res. 2021;35:5440\u201358.","journal-title":"Phytother Res"},{"key":"6234_CR35","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3390\/antiox9060521","volume":"9","author":"RT Ruhee","year":"2020","unstructured":"Ruhee RT, Suzuki K. The integrative role of sulforaphane in preventing inflammation, oxidative stress and fatigue: a review of a potential protective phytochemical. Antioxid. 2020;9:521.","journal-title":"Antioxid"},{"key":"6234_CR36","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jdermsci.2013.02.006","volume":"70","author":"XY Yin","year":"2013","unstructured":"Yin XY, Cheng H, Wang WJ, Wang WJ, Fu HY, Liu LH, et al. TNIP1\/ANXA6 and CSMD1 variants interacting with cigarette smoking, alcohol intake affect risk of psoriasis. J Dermatol Sci. 2013;70:94\u20138.","journal-title":"J Dermatol Sci"},{"key":"6234_CR37","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.freeradbiomed.2009.06.033","volume":"47","author":"Q Zhou","year":"2009","unstructured":"Zhou Q, Mrowietz U, Rostami-Yazdi M. Oxidative stress in the pathogenesis of psoriasis. Free Radic Biol Med. 2009;47:891\u2013905.","journal-title":"Free Radic Biol Med"},{"key":"6234_CR38","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00403-014-1470-x","volume":"306","author":"Y Lee","year":"2014","unstructured":"Lee Y, Shin JM, Jang S, Choi DK, Seo MS, Kim HR, et al. Role of nuclear factor E2-related factor 2 (Nrf2) in epidermal differentiation. Arch Dermatol Res. 2014;306:677\u201382.","journal-title":"Arch Dermatol Res"},{"key":"6234_CR39","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1016\/j.jid.2016.04.022","volume":"136","author":"Y Ishitsuka","year":"2016","unstructured":"Ishitsuka Y, Huebner AJ, Rice RH, Koch PJ, Speransky VV, Steven AC, et al. Lce1 family members are Nrf2-target genes that are induced to compensate for the loss of loricrin. J Invest Dermatol. 2016;136:1656\u201363.","journal-title":"J Invest Dermatol"},{"key":"6234_CR40","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1124\/jpet.114.218818","volume":"352","author":"I Helwa","year":"2015","unstructured":"Helwa I, Patel R, Karempelis P, Kaddour-Djebbar I, Choudhary V, Bollag WB. The antipsoriatic agent monomethylfumarate has antiproliferative, prodifferentiative, and anti-inflammatory effects on keratinocytes. J Pharm Exp Ther. 2015;352:90\u201397.","journal-title":"J Pharm Exp Ther"},{"key":"6234_CR41","doi-asserted-by":"publisher","first-page":"100040","DOI":"10.1016\/j.xjidi.2021.100040","volume":"1","author":"K Bojanowski","year":"2021","unstructured":"Bojanowski K, Ibeji CU, Singh P, Swindell WR, Chaudhuri RK. A sensitization-free dimethyl fumarate prodrug, isosorbide di-(methyl fumarate), provides a topical treatment candidate for psoriasis. JID Innov. 2021;1:100040.","journal-title":"JID Innov"},{"key":"6234_CR42","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/biof.1912","volume":"49","author":"E Panieri","year":"2022","unstructured":"Panieri E, Telkoparan-Akillilar P, Saso L. NRF2, a crucial modulator of skin cells protection against vitiligo, psoriasis, and cancer. Biofactors. 2022;49:228\u2013250.","journal-title":"Biofactors"},{"key":"6234_CR43","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3390\/ijms19010171","volume":"19","author":"E Calautti","year":"2018","unstructured":"Calautti E, Avalle L, Poli V. Psoriasis: a STAT3-Centric view. Int J Mol Sci. 2018;19:171.","journal-title":"Int J Mol Sci"},{"key":"6234_CR44","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1080\/1744666X.2020.1771182","volume":"16","author":"P Gisondi","year":"2020","unstructured":"Gisondi P, Geat D, Conti A, Dapavo P, Piaserico S, De Simone C, et al. TNF-\u03b1 inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis. Expert Rev Clin Immunol. 2020;16:591\u20138.","journal-title":"Expert Rev Clin Immunol"},{"key":"6234_CR45","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1091\/mbc.12.11.3439","volume":"12","author":"MJ Wawersik","year":"2001","unstructured":"Wawersik MJ, Mazzalupo S, Nguyen D, Coulombe PA. Increased levels of keratin 16 alter epithelialization potential of mouse skin keratinocytes in vivo and ex vivo. Mol Biol Cell. 2001;12:3439\u201350.","journal-title":"Mol Biol Cell"},{"key":"6234_CR46","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1097\/CM9.0000000000001197","volume":"133","author":"CY Xiao","year":"2020","unstructured":"Xiao CY, Zhu ZL, Zhang C, Fu M, Qiao HJ, Wang G, et al. Small interfering RNA targeting of keratin 17 reduces inflammation in imiquimod-induced psoriasis-like dermatitis. Chin Med J. 2020;133:2910\u20138.","journal-title":"Chin Med J"},{"key":"6234_CR47","doi-asserted-by":"publisher","first-page":"120561","DOI":"10.1016\/j.lfs.2022.120561","volume":"300","author":"M Sadrkhanloo","year":"2022","unstructured":"Sadrkhanloo M, Entezari M, Orouei S, Zabolian A, Mirzaie A, Maghsoudloo A, et al. Targeting Nrf2 in ischemia-reperfusion alleviation: from signaling networks to therapeutic targeting. Life Sci. 2022;300:120561.","journal-title":"Life Sci"},{"key":"6234_CR48","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1089\/ars.2017.7358","volume":"29","author":"N Keleku-Lukwete","year":"2018","unstructured":"Keleku-Lukwete N, Suzuki M, Yamamoto M. An overview of the advantages of KEAP1-NRF2 system activation during inflammatory disease treatment. Antioxid Redox Signal. 2018;29:1746\u201355.","journal-title":"Antioxid Redox Signal"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06234-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06234-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06234-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T04:02:30Z","timestamp":1700884950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06234-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,25]]},"references-count":48,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["6234"],"URL":"https:\/\/doi.org\/10.1038\/s41419-023-06234-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2800948\/v1","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,25]]},"assertion":[{"value":"11 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All relevant ethics documents were approved by the Institutional Research Ethics Committee of Nanjing Medical University (for clinical patients) and Nanjing University (for mice).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"768"}}